| Wissenschaftl. Titel | A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
| Erkrankung |
Gastro:
Magen-/Ösophaguskarzinom:
Alle Linien
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (MZ) Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 23.11.2020 Data entry XI CCP
geändert 11.10.2022 Data entry III CCP